Fluoropharma Competitors

Pink Sheets . USA . 
Stock . Fluoropharma Medical
FPMI Stock  USD 0.0001  0.00  0.00%   
Fluoropharma Medical competes with Brainsway, Venus Concept, Tactile Systems, Icecure Medical, and SurModics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Fluoropharma Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Fluoropharma Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Fluoropharma Medical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Fluoropharma Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details
Naive
Forecast
LowNextHigh
0.00010.00010.0001
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00010.00010.0001
Details

Fluoropharma Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Fluoropharma Medical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Fluoropharma and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Fluoropharma Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RPID
+ 0.71
BWAY
TNON
+ 0.61
VERO
RPID
+ 0.6
TCMD
BBLG
+ 0.52
VERO
TIVC
+ 0.52
SSKN
TCMD
+ 0.5
BWAY
  
High negative correlations   
RPID
- 0.65
VERO
VERO
- 0.62
BWAY
TCMD
- 0.58
VERO
SRDX
- 0.56
BWAY
RPID
- 0.52
TNON
TNON
- 0.52
TCMD

Risk-Adjusted Indicators

There is a big difference between Fluoropharma Pink Sheet performing well and Fluoropharma Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Fluoropharma Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BWAY  2.41  0.23  0.08  0.31  2.87 
(2.71)
 5.42 
(4.76)
 24.68 
VERO  6.69 (0.70) 0.00 (0.10) 0.00 
 0.00 
 14.71 
(13.79)
 94.50 
TCMD  2.19  0.46  0.18  0.41  2.45 
(2.54)
 5.99 
(3.29)
 15.80 
ICCM  3.54  0.51  0.08 (3.45) 3.44 
(5.81)
 9.86 
(6.90)
 30.34 
SRDX  0.48 (0.06) 0.00 (0.03) 0.00 
 0.00 
 1.26 
(1.01)
 3.22 
SSKN  2.87 (0.14) 0.00 (0.19) 0.00 
 0.00 
 5.50 
(7.20)
 16.58 
TIVC  4.66 (0.11) 0.00 (0.02) 0.00 
 0.00 
 12.12 
(6.90)
 79.31 
BBLG  9.09  0.81  0.09  0.69  8.77 
(14.60)
 18.13 
(17.14)
 163.17 
TNON  7.95 (0.11) 0.00 (0.10) 0.00 
 0.00 
 34.08 
(16.00)
 90.53 
RPID  2.32  0.22  0.08  0.31  2.66 
(2.79)
 5.88 
(4.55)
 24.78 
All Fundamental Data

Fluoropharma Medical Competitive Analysis

The better you understand Fluoropharma Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Fluoropharma Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Fluoropharma Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
FPMI BWAY VERO TCMD ICCM SRDX SSKN TIVC BBLG TNON
 0.00 
 0.0001 
Fluoropharma
 1.96 
 9.87 
Brainsway
 5.88 
 0.32 
Venus
 3.22 
 19.54 
Tactile
 5.06 
 0.83 
Icecure
 0.23 
 39.45 
SurModics
 3.96 
 3.15 
STRATA
 4.00 
 0.26 
Tivic
 3.17 
 1.22 
Bone
 2.14 
 2.29 
Tenon
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Extremely Dangerous
Not too volatile
Extremely Dangerous
Very steady
Unstable
Out of control
Very risky
Abnormally volatile
Market Performance
(90 Days Performance)
Very Weak
Good
Very Weak
Good
OK
Weak
Very Weak
Very Weak
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Very High
Very Small
Low
Low
High
Very High
High
Very High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Hold
Buy
Strong Buy
Hold
Buy
Not Available
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
6.85
2.74
2.31
4.99
2.04
1.3
4.36
80.11
7.54
Net Asset
334.76 K
62.97 M
93.65 M
281.44 M
16.41 M
178.56 M
42.02 M
5.16 M
3.74 M
6.34 M
Profit Margin
N/A
0.0167
-0.72
0.0542
N/A
-0.0916
-0.25
N/A
N/A
N/A
EBITDA
(2.16 M)
(2.31 M)
(26.11 M)
24.54 M
(15.25 M)
1.19 M
(3.38 M)
(8.06 M)
479.57 K
(15.53 M)
Current Valuation
9.23 M
135.16 M
36.2 M
419.37 M
36 M
558.29 M
22.55 M
(81.15 K)
(560.91 K)
2.27 M
Price To Book
17.76
4.21
0.23
2.26
4.59
4.75
1.41
0.74
0.79
1.62
Operating Margin
N/A
0.0586
-0.34
0.0928
-3.19
-0.0185
-0.0576
-8.61
N/A
-4.3
Retained Earnings
(34.16 M)
(101.3 M)
(261.9 M)
18.89 M
(90.06 M)
75.71 M
(238.06 M)
(37.89 M)
(80.91 M)
(55.07 M)
Current Asset
89 K
N/A
N/A
64.23 M
N/A
58.56 M
9.39 M
N/A
1.07 M
N/A
Beta
-59.92
0.37
0.64
1.17
2.63
1.2
1.32
2.41
0.74
2.16
Number Of Employees
4
134
304
992
71
N/A
99
9
2
21
Shares Outstanding
34.26 M
18.78 M
7.26 M
24 M
55.5 M
14.33 M
4.17 M
8.27 M
2.46 M
3.14 M
Cash Flow From Operations
(880.12 K)
1.28 M
(12.86 M)
35.85 M
(12.52 M)
248 K
(519 K)
(8.51 M)
(9.56 M)
(12.18 M)
Total Debt
5.82 M
471 K
79.7 M
50.38 M
599 K
33.24 M
15.63 M
369 K
831.4 K
1.86 M
Return On Equity
N/A
0.0144
-4.64
0.0791
-0.94
-0.0967
-0.63
-1.84
-1.19
-15.99
Return On Asset
-2.35
0.0073
-0.19
0.0462
-0.47
-0.0066
-0.0679
-0.89
-0.57
-1.1
Book Value Per Share
-0.3
1.25
-2.53
8.66
0.27
8.38
3.62
2.44
5.44
2.39
Number Of Shares Shorted
N/A
30.6 K
108.59 K
978.4 K
2.31 M
348.4 K
7 K
1.23 M
58.17 K
135.41 K
Current Liabilities
10.32 M
N/A
N/A
13.79 M
N/A
10.13 M
4.62 M
N/A
2.16 M
N/A
Total Asset
334.76 K
62.97 M
93.65 M
281.44 M
16.41 M
178.56 M
42.02 M
5.16 M
3.74 M
6.34 M
Debt To Equity
0.07
0.013
7.84
0.66
0.039
0.12
0.35
0.077
N/A
0.067
Target Price
2.5
13.73
10.6
24.0
3.37
43.0
16.0
210.0
16.75
8.0
Short Ratio
N/A
0.33
0.69
4.08
0.46
1.49
0.44
0.12
0.18
0.11
Shares Owned By Institutions
0.34
19.22
27.03
98.05
0.39
83.07
60.39
3.64
4.58
1.8
Market Capitalization
3.43 M
185.39 M
2.49 M
468.9 M
46.19 M
566.45 M
13.14 M
2.11 M
3.1 M
7.34 M
Price To Earning
-0.39
N/A
N/A
23.07
N/A
69.21
-0.49
N/A
-15.45
N/A
Price To Earnings To Growth
N/A
N/A
N/A
17.24
N/A
3.9
-0.02
N/A
N/A
N/A
Price To Sales
N/A
5.09
0.0356
1.65
13.85
4.49
0.4
1.89
N/A
2.18
Net Income
(2.05 M)
(4.2 M)
(37.05 M)
28.52 M
(14.65 M)
(11.54 M)
(10.83 M)
(8.24 M)
(8.95 M)
(15.58 M)
Earnings Per Share
-0.077
0.08
-7.97
0.65
-0.28
-0.82
-2.6
5.37
-1.46
287.92
Shares Owned By Insiders
N/A
N/A
6.07
1.95
54.17
3.73
2.91
0.25
5.21
1.7
Revenue
N/A
31.79 M
76.35 M
274.42 M
3.23 M
126.08 M
33.36 M
1.18 M
N/A
2.93 M
Working Capital
(10.23 M)
45.7 M
44.41 M
104.24 M
10.31 M
60.76 M
3.37 M
3.25 M
2.91 M
6.82 M
Cash And Equivalents
24.72 K
49.62 M
6.78 M
23.35 M
17.73 M
22.09 M
10.04 M
9.06 M
5.45 M
16.02 M
Cash Per Share
N/A
2.95
0.1
1.16
0.48
1.58
0.29
0.94
0.53
1.42
Gross Profit
N/A
20.05 M
74.09 M
175.98 M
1.45 M
29 M
19.85 M
(129 K)
N/A
(641 K)
Day Typical Price
1.0E-4
9.82
0.33
19.4
0.83
39.48
3.07
0.25
1.21
2.3
Accumulation Distribution
N/A
0.039
0.0588
0.042
0.0353
0.004
0.0794
0.0769
0.15
0.0258
Market Facilitation Index
N/A
0.39
0.02
0.83
0.03
0.16
0.25
0.02
0.2
0.06
Daily Balance Of Power
0.0
0.4872
(1.00)
0.7349
1.333333
(0.56)
0.48
0.5
(0.20)
(0.83)
Period Momentum Indicator
N/A
0.19
(0.02)
0.61
0.04
(0.09)
0.12
0.01
(0.04)
(0.05)
Rate Of Daily Change
1.0
1.02
0.94
1.03
1.05
1.0
1.04
1.04
0.97
0.98
Day Median Price
1.0E-4
9.8
0.33
19.34
0.84
39.5
3.03
0.25
1.2
2.3
Price Action Indicator
N/A
0.17
(0.02)
0.51
0.015
(0.1)
0.19
0.015
N/A
(0.04)
Relative Strength Index
N/A
75.28
42.18
64.54
39.28
61.57
51.49
70.7
38.75
45.68
Coefficient Of Variation
N/A
872.05
(3,960)
471.24
1048.61
(31,373)
(5,261)
(222,194)
1944.92
(35,858)
Mean Deviation
N/A
2.41
6.69
2.19
3.54
0.4826
2.87
4.66
9.09
7.95
Jensen Alpha
N/A
0.2277
(0.70)
0.4554
0.5112
(0.06)
(0.14)
(0.11)
0.8074
(0.11)
Total Risk Alpha
N/A
(0.19)
(2.33)
0.1336
(0.39)
(0.12)
(0.71)
(1.56)
(2.26)
(2.44)
Sortino Ratio
N/A
0.0825
N/A
0.1831
0.0838
N/A
N/A
N/A
0.0898
N/A
Downside Variance
N/A
9.8
N/A
8.56
19.0
N/A
N/A
N/A
92.17
N/A
Standard Deviation
N/A
3.45
12.05
3.17
5.27
0.6575
3.78
9.26
19.45
14.34
Kurtosis
N/A
4.41
19.79
4.27
3.2
1.46
0.1071
23.57
36.65
10.58
Potential Upside
N/A
5.42
14.71
5.99
9.86
1.26
5.5
12.12
18.13
34.08
Treynor Ratio
N/A
0.3114
(0.10)
0.4073
(3.45)
(0.03)
(0.19)
(0.02)
0.6911
(0.10)
Maximum Drawdown
N/A
24.68
94.5
15.8
30.34
3.22
16.58
79.31
163.17
90.53
Variance
N/A
11.91
145.26
10.06
27.82
0.4324
14.26
85.84
378.41
205.52
Market Risk Adjusted Performance
N/A
0.3214
(0.09)
0.4173
(3.44)
(0.02)
(0.18)
(0.01)
0.7011
(0.09)
Risk Adjusted Performance
N/A
0.0954
(0.01)
0.1698
0.0815
(0)
(0.01)
0.0088
0.0489
0.0073
Skewness
N/A
0.5768
3.47
0.246
1.14
0.7044
0.0441
3.82
5.23
2.83
Semi Deviation
N/A
2.87
N/A
2.45
3.44
N/A
N/A
N/A
8.77
N/A
Information Ratio
N/A
0.0748
(0.04)
0.1688
0.0693
(0.21)
(0.06)
(0.02)
0.0443
(0.01)
Value At Risk
N/A
(4.76)
(13.79)
(3.29)
(6.90)
(1.01)
(7.20)
(6.90)
(17.14)
(16.00)
Expected Short fall
N/A
(2.71)
N/A
(2.54)
(5.81)
N/A
N/A
N/A
(14.60)
N/A
Downside Deviation
N/A
3.13
N/A
2.93
4.36
N/A
N/A
N/A
9.6
N/A
Semi Variance
N/A
8.25
N/A
6.02
11.86
N/A
N/A
N/A
76.83
N/A

Fluoropharma Medical Competition Performance Charts

Five steps to successful analysis of Fluoropharma Medical Competition

Fluoropharma Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Fluoropharma Medical in relation to its competition. Fluoropharma Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Fluoropharma Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Fluoropharma Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Fluoropharma Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Fluoropharma Medical position

In addition to having Fluoropharma Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sports Thematic Idea Now

Sports
Sports Theme
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Fluoropharma Pink Sheet

Fluoropharma Medical financial ratios help investors to determine whether Fluoropharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fluoropharma with respect to the benefits of owning Fluoropharma Medical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY